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Macrophage Glucose-6-Phosphate Dehydrogenase Stimulates
Proinflammatory Responses with Oxidative Stress
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Hiroaki Masuzaki,c Jae Bum Kima,b
School of Biological Sciences, Institute of Molecular Biology and Genetics, National Creative Research Initiatives Center for Adipose Tissue Remodeling,a and Department
of Biophysics and Chemical Biology,b Seoul National University, Seoul, South Korea; Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology,
Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japanc; Division of Endocrinology and Metabolism, Department of Medicine, University of
California, San Diego, San Diego, California, USAd
Glucose-6-phosphate dehydrogenase (G6PD) is a key enzyme that regulates cellular redox potential. In this study, we demon-
strate that macrophage G6PD plays an important role in the modulation of proinflammatory responses and oxidative stress. The
G6PD levels in macrophages in the adipose tissue of obese animals were elevated, and G6PDmRNA levels positively correlated
with those of proinflammatory genes. Lipopolysaccharide (LPS) and free fatty acids, which initiate proinflammatory signals,
stimulated macrophage G6PD. Overexpression of macrophage G6PD potentiated the expression of proinflammatory and pro-
oxidative genes responsible for the aggravation of insulin sensitivity in adipocytes. In contrast, whenmacrophage G6PDwas
inhibited or suppressed via chemical inhibitors or small interfering RNA (siRNA), respectively, basal and LPS-induced proin-
flammatory gene expression was attenuated. Furthermore, macrophage G6PD increased activation of the p38 mitogen-activated
protein kinase (MAPK) and NF-B pathways, which may lead to a vicious cycle of oxidative stress and proinflammatory cascade.
Together, these data suggest that an abnormal increase of G6PD inmacrophages promotes oxidative stress and inflammatory
responses in the adipose tissue of obese animals.
Obesity is a key risk factor for metabolic diseases, includinghyperlipidemia, atherosclerosis, hypertension, insulin resis-
tance, and type 2 diabetes (1, 2). During the past few decades, the
mechanisms linking obesity to metabolic diseases have been in-
tensively investigated, and accumulating evidence suggests that
the adipose tissue of the obese exhibits chronic and low-grade
inflammation, which is closely associatedwithmetabolic dysregu-
lation (3). In obesity, adipose tissue macrophages (ATMs) pro-
duce various proinflammatory cytokines and chemokines, such as
tumor necrosis factor alpha (TNF-) (4), interleukin-6 (IL-6),
and monocyte chemoattractant protein 1 (MCP-1), whose eleva-
tion mediates metabolic dysregulation and insulin resistance (5–
8). Accordingly, MCP-1 and CCR2 (MCP-1 receptor) knockout
mice are protected from insulin resistance and have a decreased
number of ATMs, suggesting that proinflammatory cytokines and
chemokines are essential for the recruitment of ATMs and disrup-
tion of insulin sensitivity in obesity (6, 7).
Macrophages are the major effector cells that constitute the
innate immune systemandperformmultiple roles, such as phago-
cytosis, secretion of cytokines and chemokines, and antigen pre-
sentation, when they recognize pathogens or cellular debris (9).
These responses are mediated by the generation of reactive oxy-
gen/reactive nitrogen species (ROS/RNS), such as superoxide
(·O2
), hydrogen peroxide (H2O2), nitric oxide (·NO
), and per-
oxynitrite (ONOO) (10), which play a key role in killing bacteria
and delivering signals as second messengers (11). ROS and RNS
participate in various signaling pathways by activating and phos-
phorylating mitogen-activated protein kinases (MAPKs), includ-
ing extracellular signal-regulated protein kinase (ERK), c-Jun N-
terminal kinase (JNK), and p38MAPK isoforms. In addition, ROS
contributes to the regulation of gene expression throughmodula-
tion of several transcription factors, including NF-B (12), c-Fos,
and c-Jun (13), which are responsible for the expression of proin-
flammatory cytokines, chemokines, and signaling components.
Endogenous ROS is generated by both nonenzymatic and en-
zymatic reactions (14). Mitochondria are a major source of non-
enzymatic ROS production (15). However, in macrophages,
abundant ROS is generated by enzymatic reactions of multicom-
ponent NADPH oxidase 2 (NOX2) (16). Upon phagocytosis
and/or various stimuli, NOX2 transfers 1 electron from NADPH
to oxygen to generate a superoxide anion. In addition, endoge-
nous nitric oxide is enzymatically produced by inducible nitric
oxide synthases (iNOS) through the oxidation of L-arginine in the
presence of oxygen and NADPH (14). Because NOX2 and iNOS
require NADPH in common, sufficient NADPH is necessary to
produce cellular ROS and RNS in macrophages.
Glucose-6-phosphate dehydrogenase (G6PD), the first and
rate-limiting enzyme of the pentose phosphate pathway (PPP), is
a key enzyme in the generation of cytosolic NADPH. G6PD par-
ticipates in multiple metabolic pathways, such as reductive bio-
synthesis, regulation of oxidative stress, and cellular growth. We
previously demonstrated that G6PD is highly expressed in the
adipocytes of obese animals, and its overexpression in adipocytes
impairs lipid homeostasis and adipocytokine expression, resulting
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in insulin resistance (17). We also showed that increased adi-
pocyte and pancreatic -cell G6PD is closely associated with oxi-
dative stress in the onset ofmetabolic disorders (18, 19).However,
the functions of macrophage G6PD in pathophysiological condi-
tions such as obesity have not been fully elucidated. Since oxida-
tive stress is a critical factor in the regulation of macrophages’
proinflammatory roles, we hypothesized that macrophage G6PD
might be a crucial enzyme that affects cellular redox and inflam-
matory cascades in response to metabolic changes.
In the present study,we demonstrate thatmacrophageG6PD is
involved in the proinflammatory responses, accompanied by ox-
idative stress. G6PD is highly expressed in ATMs, and its expres-
sion level is significantly higher in obese animals. Inmacrophages,
G6PD stimulates the expression of ROS- and RNS-producing
genes and increases the levels of inflammatory cytokines, includ-
ing IL-6, IL-1, MCP-1, and TNF-, which attenuate insulin sig-
naling in adipocytes. Furthermore, macrophage G6PD activates
p38 MAPK and NF-B, which are key regulators of oxidative
stress and proinflammatory responses. Taken together, these data
suggest that macrophage G6PD enhances oxidative stress and in-
flammatory signaling, which may lead to insulin resistance in the
adipose tissue of obese animals.
MATERIALS AND METHODS
Animals. C57BL6/J mice were purchased from Central Lab Animal Inc.
(Seoul, SouthKorea) andwere housed in colony cages in a 12-h light/12-h
dark cycle. After a minimum of 1 week for stabilization, the mice were fed
a normal chow diet (NCD) or high-fat diet (HFD) for 10 weeks (Research
Diets Inc., New Brunswick, NJ). Eight-week-old C57BLKS/J-Leprdb/
Leprdb mice were obtained from Central Lab Animal Inc. (Seoul, South
Korea). All animal procedures were in accordance with the research
guidelines for the use of laboratory animals of Seoul National University.
Reagents and inhibitors. Dehydroepiandrosterone (DHEA), 6-ami-
nonicotinamide (6-AN), lipopolysaccharide (LPS), N-acetyl-L-cysteine
(NAC), hydrogen peroxide, NADPH (NADP, reduced), free fatty acid
(FFA) (palmitic acid), SB 203580, PD 98059, and SP 600125 were pur-
chased from Sigma (St. Louis, MO).
Cell culture. RAW 264.7 macrophages were purchased from the
American TypeCulture Collection (Manassas, VA). RAW264.7 cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM) (HyClone, Lo-
gan, UT) supplemented with 10% fetal bovine serum (FBS), 100 U/ml
penicillin, and 100mg/ml streptomycin. Cells were maintained at 37°C in
a humidified atmosphere containing 5%CO2. 3T3-L1 preadipocytes were
maintained in DMEM supplemented with 10% bovine calf serum. To
differentiate 3T3-L1 cells, they were grown to confluence and stimulated
withDMEMcontaining 10% fetal bovine serum, dexamethasone (1M),
methylisobutylxanthine (520 M), and insulin (167 nM) for 48 h. Then,
the culture medium was exchanged for DMEM containing 10% fetal bo-
vine serum and insulin (167 nM) for another 48 h, and 3T3-L1 cells were
maintained with DMEM containing 10% fetal bovine serum.
Fractionation of mouse adipose tissues. To prepare stromal vascular
cells (SVCs) from adipose tissue, mice were sacrificed. Gonadal fat pads
were isolated and incubated in 30ml of collagenase buffer (0.1MHEPES,
pH 7.4, 0.125 M NaCl, 50 mM KCl, 1.3 mM CaCl2, 0.5 M glucose, 0.45 g
bovine serum albumin [BSA], and 30 mg of collagenase) at 37°C for 40
min with shaking and shearing. Then, the treated tissues were filtered
through 100-m-pore-size nylon mesh to remove debris and centrifuged
at 930  g for 3 min. SVCs were obtained in the pellet. To remove red
blood cells (RBCs), the pellet was incubated in RBC lysis buffer (1.7 M
Tris, pH 7.65, and 0.16 M NH4Cl) for 15 min. After RBC lysis, the SVCs
were washed several times with phosphate-buffered saline (PBS).
Flow cytometry analysis. For macrophage G6PD analysis, SVCs were
stained with CD11b (BD Bioscience, San Jose, CA) and F4/80 (eBiosci-
ence, San Diego, CA) monoclonal antibodies (MAbs) for 20 min at 4°C.
After mild washing, SVCs were fixed and permeabilized with BD Cytofix/
Cytoperm, following themanufacturer’s instructions (BDBioscience, San
Jose, CA). G6PD antibody purchased from Abcam (Cambridge, United
Kingdom) was used to stain intracellular G6PD. SVCs were analyzed us-
ing the fluorescence-activated cell sorting (FACS) CantoII instrument
(BD Bioscience, San Jose, CA).
Isolation of peritoneal macrophages. Mice were stimulated by an
intraperitoneal injection of a thioglycolate solution (3 ml per mouse) and
kept under pathogen-free conditions for 3 days before peritoneal macro-
phage isolation. Total peritoneal macrophages were harvested by washing
the peritoneal cavitywith PBS containing 30mMEDTA (8ml permouse).
The peritoneal wash fluidwas centrifuged, and the cells were suspended in
RPMI 1640 medium (HyClone, Logan, UT) with 10% FBS (HyClone,
Logan,UT), 100U/ml penicillin, and 100mg/ml streptomycin. Peritoneal
macrophages were maintained at 37°C in a humidified atmosphere con-
taining 5% CO2. Nonadherent cells were removed after the cells firmly
adhered to culture dishes.
qRT-PCR analysis. Total RNA was isolated from RAW 264.7 macro-
phages, mouse peritoneal macrophages, and SVCs using Isol-RNA lysis
reagent (5 Prime, Hamburg, Germany). cDNA was synthesized using
Moloney murine leukemia virus (M-MuLV) reverse transcriptase (Fer-
mentas, Glen Burnie, MD). For quantitative reverse transcription-PCR
(qRT-PCR) reactions, the amplification was performed with SYBR green
for 35 cycles of 95°C for 30 s, 58°C for 30 s, and 72°C for 30 s, followed by
a final extension at 72°C for 5 min. The primers were designed and syn-
thesized byBioneer (Daejeon, SouthKorea), and the primer sequences are
shown in Table S1 in the supplemental material.
Measurement of cellular nitrate and ROS levels. Nitrite was mea-
sured using the Griess reaction (20). Culture media (100 l) were col-
lected and incubated with an equal volume of Griess reagent for 10min at
room temperature. The nitrite concentration was determined by the ab-
sorbance at 550 nm, using sodium nitrite as a standard. Cellular ROS was
measured using chloromethyl-2=,7=-dichlorodihydrofluorescein diace-
tate (chloromethyl-H2DCFDA) (Invitrogen, Grand Island, NY). RAW
264.7 macrophages and peritoneal macrophages were incubated with
DCFDA in the dark for 20min and washed with PBS. Cells were detached
from culture dishes and suspended in ice-cold PBS for fluorescence mea-
surement using flow cytometry (BD Bioscience, San Jose, CA).
Measurement of cytokine secretion. Secretion of IL-6 and MCP-1
into conditioned medium was measured with an enzyme-linked immu-
nosorbent assay (ELISA) according to the manufacturer’s instructions
(BioSource, Grand Island, NY).
Western blot analysis.Western blot analysis was performed as pre-
viously described (21), with a minor modification. The cells were lysed
with TGN buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Tween 20,
0.2% NP-40, and protease inhibitor cocktail [GenDepot, Houston,
TX]) and subjected to Western blotting. Equal amounts of protein (50
g) were separated on SDS-PAGE gels and transferred to polyvi-
nylidene difluoride (PVDF) membranes. The blots were blocked with
5% nonfat milk in TBST (25 mM Tris, pH 8.0, 137 mM NaCl, 2.7 mM
KCl, and 0.1% Tween 20) at room temperature for 30 min, followed by
overnight incubation with primary antibodies at 4°C. After washing 3
times with TBST, the blots were hybridized with horseradish peroxi-
dase-conjugated secondary antibodies (Bio-Rad, Hercules, CA) in 5%
nonfat milk dissolved in TBST at room temperature for 2 h and washed
3 times with TBST. The results were visualized with enhanced chemi-
luminescence. G6PD and -actin antibodies were purchased from
Sigma (St. Louis, MO); phospho-AKT, phospho-glycogen synthase
kinase 3 (phospho-GSK3), phospho-JNK, and phospho-ERK anti-
bodies were purchased from Cell Signaling Technology (Danvers,
MA); AKT, GSK3, and phospho-p38 MAPK antibodies were pur-
chased from BD Bioscience (San Jose, CA); and iNOS, p38 MAPK,
ERK, and JNK antibodies were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA).
Ham et al.
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Adenovirus infection. G6PD adenovirus (Ad-G6PD) was produced
by Neurogenex (Seoul, South Korea). G6PD cDNA was fused in frame
with a FLAG epitope tag at its NH2 terminus, which was cloned into an
adenoviral vector, pEntrBHRNX. An empty adenovirus vector (Ad-
mock) was used as control. For adenoviral infection, primary macro-
phageswere incubatedwith serum-freeDMEMand adenovirus for 12 h at
37°C. Then, the culture medium was replaced with fresh medium. Each
experiment was performed 48 h after viral infection.
Transfection with DNA and siRNA.DNA and small interfering RNA
(siRNA) were delivered into RAW 264.7 macrophages using electropora-
tion, and then the experiments were conducted at least 24 h after trans-
fection. Mouse G6PD cDNA was cloned into pcDNA3.1 (Invitrogen,
Grand Island, NY). The sequences of the siRNAs targeting G6PD
(siG6PD) and the p50 subunit of NF-B (siNF-B p50) are provided in
Table S2 in the supplemental material. As a negative control, siGFP or
siNC, neither of which has a target sequence in the mouse genome, was
used for transfection experiments.
Conditioned-medium experiment. RAW 264.7 macrophages were
transfected with enhanced green fluorescent protein (EGFP) or G6PD
expression vector, and conditioned media were collected 24 h after trans-
fection. Fully differentiated 3T3-L1 adipocytes were incubated with con-
ditionedmedia for 24 h and stimulated with insulin (100 nM) for 30min.
Analysis of human fat tissue. The present study was performed in
accordance with the Declaration of Helsinki and was approved by the
Ethical Committee on Human Research of Kyoto University Graduate
School of Medicine (2004; no. 553). Signed informed consent was ob-
tained from all subjects. Seventy Japanese subjects (32 men and 38 women;
ages, 47 1.9 years; bodymass index [BMI], 28 1.0 kg/m2 [range, 18 to
55 kg/m2]) were recruited for the study. Among the subjects, 41 with a
BMI of 24 to 55 kg/m2 were admitted to the Division of Endocrinology
andMetabolismofKyotoUniversityHospital for the treatment of obesity,
hypertension, dyslipidemia, or type 2 diabetes mellitus. Waist circumfer-
ence wasmeasured at the umbilicus in an upright position. Blood samples
were obtained at 0800 h after fasting overnight and 3 days before the
adipose tissue biopsies. Subcutaneous- and visceral-fat areas were evalu-
ated at the umbilical level by computerized tomography (n  33)
(Toshiba Medical Systems, Tokyo, Japan). Subcutaneous abdominal adi-
pose tissue (SAT) biopsies were done in the morning after breakfast. The
SAT (	2 g) was removed from the periumbilical region under local an-
esthesia (1% lidocaine). Samples were immediately frozen in liquid nitro-
gen and stored at80°C until use.
Whole-mount immunohistochemistry. Mice were anesthetized by
an intramuscular injection of a combination of anesthetics. After fixation
by vascular perfusion of 1% paraformaldehyde in PBS, adipose tissues
were isolated. The whole-mount tissues were then incubated for 1 h at
room temperature with a blocking solution containing 5% goat serum
(Jackson ImmunoResearch) in 0.3% PBS-Tween (PBST). After blocking,
the whole-mount tissues were incubated overnight at 4°C with antibodies
against F4/80 (clone Cl:A3-1, diluted 1:1,000; Serotec) andG6PD (diluted
1:500; Bethyl). After several washes with PBST, the whole-mount tissues
were incubated for 1 h at room temperature with secondary antibodies,
namely, Cy3- or Cy5-conjugated anti-rat antibody or anti-rabbit anti-
body (diluted 1:500; Jackson ImmunoResearch). The signals were visual-
ized, and digital imageswere obtained using a Zeiss ApoTomemicroscope
and a Zeiss LSM510 confocal microscope equipped with argon and
helium-neon lasers (Carl Zeiss).
Luciferase assay. An NF-B–luciferase reporter gene and EGFP or
G6PD were cotransfected into RAW 264.7 macrophages by electropora-
tion. After transfection, each group was treated with DHEA, 6-AN, or SB
203580 for 24 h. Luciferase assays were performed, and the results are
expressed as relative luciferase units (luciferase activity/g protein).
RESULTS
Macrophage G6PD expression is higher in obese subjects. Pre-
viously, we reported that G6PD expression is elevated in the adi-
pose tissue of obese and diabetic db/db mice (17). To investigate
whether the level of G6PD expression in ATMs is correlated with
adiposity, G6PDmRNA levels weremeasured in the SVC fractions
of epididymal fat tissues from obese-mousemodels, such asHFD-
fed mice and db/dbmice. Compared to lean mice, obese mice had
higher levels of G6PD mRNA in the SVC fractions of fat tissue
(Fig. 1A and B). In addition, to examine the level of G6PD protein
in ATMs, we stained SVC fractions from lean db/
 or obese db/db
mice with fluorescence-labeled antibodies against macrophage
marker (CD11b and F4/80) andG6PD. By flow cytometry, CD11b
and F4/80 double-positive cells were selected to measure the level
of G6PD protein. As shown in Fig. 1C, the level of ATM G6PD
protein was higher in db/dbmice than in db/
mice. To confirm
this, we also performed whole-tissue immunohistochemistry.
Compared to lean mice, G6PD-positive signals were enhanced
and were colocalized with CD11b-positive macrophages in the
adipose tissue of db/db mice (Fig. 1D). Similarly, G6PD was also
increased and colocalized with macrophage marker in HFD-fed
obese mice compared to NCD-fed lean mice (see Fig. S1 in the
supplemental material). When G6PD expression was analyzed in
human adipose tissue, the levels of G6PD mRNA were positively
correlated with several indices of obesity—BMI, waist circumfer-
ence, and visceral-fat area—but not subcutaneous-fat area, which
is rarely associated with metabolic diseases (Fig. 1E). In addition,
insulin resistance, assessed by the insulin resistance index (IRI)
and the homeostasis model assessment for insulin resistance
(HOMA-IR), was positively correlated with the level of adipose
G6PD mRNA (Fig. 1F). Moreover, the mRNA levels of macro-
phage marker genes (CD68 and MAC1) and MCP-1 were posi-
tively correlatedwith the level of G6PDmRNA in human fat tissue
(Fig. 1G). These results indicate that G6PD expression is increased
in the ATMs of obese subjects with insulin resistance.
LPS and FFAs stimulate macrophage G6PD expression. Ex-
pression of hepatic G6PD has been shown to be sensitively regu-
lated by nutritional and hormonal states (22). However, the spe-
cific stimuli responsible for the upregulation of macrophage
G6PD in obesity have not been clearly addressed. To tackle this,
RAW 264.7 macrophages were challenged with various stimuli
associated with metabolic disorders, and the levels of G6PD
mRNA and protein were examined by quantitative real-time PCR
and Western blot analyses, respectively. In macrophages, FFAs
and LPS augmented the levels of G6PD mRNA and protein, con-
comitant with increased proinflammatory cytokines, such as IL-6,
MCP-1, TNF-, and iNOS, which are known to sensitively re-
spond to both stimuli, FFAs and LPS (Fig. 2A to D). Similarly,
G6PD expression was elevated by FFA in primary macrophages
(see Fig. S2 in the supplemental material). In contrast, large
amounts of glucose or insulin did not alter G6PD expression in
macrophages (see Fig. S3 in the supplemental material). These
results imply that increase of macrophage G6PD in obesity might
be induced by FFAs and LPS, which are also elevated in obese
animals. Unlike G6PD, other cytosolic NADPH-producing en-
zymes, including isocitrate dehydrogenase 1 (IDH1) and malic
enzyme 1 (ME1), were not significantly increased inmacrophages
by LPS (Fig. 2E), suggesting that G6PD might be a key NADPH-
producing enzyme that links extracellular stimuli with the inflam-
matory cascade in macrophages.
Macrophage G6PD regulates the expression of proinflam-
matory cytokines. To characterize the roles of macrophage
G6PD, the effects of G6PD activation and inhibition on proin-
Role of Macrophage G6PD in Proinﬂammatory Cascade
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flammatory responses were investigated. In macrophages, G6PD
overexpression stimulated the expression of various proinflam-
matory cytokine genes, including IL-6, IL-1,MCP-1, andTNF-
genes (Fig. 3A). Consistently, G6PD-overexpressingmacrophages
secreted high levels of IL-6 and MCP-1 (Fig. 3B). To confirm the
effect of macrophage G6PD on proinflammatory cytokine gene
expression, G6PD expression was suppressed with siRNA. In
G6PD-suppressed macrophages, both basal and LPS-induced
IL-6 and MCP-1 mRNA expression was alleviated (Fig. 3C). In
agreement with these results, when the enzymatic activity of
G6PD was repressed by DHEA or 6-AN, LPS-induced expression
of IL-6 and MCP-1 decreased significantly (Fig. 3D and E). These
results indicate that macrophage G6PDmodulates the expression
of proinflammatory genes. Given that proinflammatory cytokines
produced from macrophages repress insulin signaling in adi-
pocytes (7, 8, 23, 24), we tested whether increase of macrophage
G6PD might affect insulin signaling in adipocytes. As shown in
Fig. 3F, conditioned media from G6PD-overexpressing macro-
phages decreased the phosphorylation of AKT and GSK3 in insu-
lin-treated adipocytes. These results suggest that elevation of macro-
FIG 1 G6PD is increased in ATMs of obese animals. (A and B) Relative levels of G6PD mRNA in SVC fractions from fat tissues of NCD-fed lean mice and
HFD-fed obese mice (A) and db/
 and db/dbmice (B). TNF- and MCP-1 mRNA was evaluated as a positive control. The values shown are normalized to the
levels of GAPDHmRNA and are reported as the mean standard deviation (SD). #, P 0.01 versus NCD or db/
 by Student’s t test. (C) Expression levels of
G6PD in ATMs of lean db/
 and obese db/dbmice. Intracellular G6PD was stained with fluorescein isothiocyanate (FITC)-conjugated antibody (FITC-A), and
the fluorescence intensity was measured using flow cytometry. The G6PD mean fluorescence intensity (MFI) is reported as the mean SD. #, P 0.01 versus
db/
by Student’s t test.One representative histogramper group is shown. (D) Expression pattern ofG6PDprotein in adipose tissue of lean db/
 andobese db/db
mice.Whole-mount immunohistochemistry analysis for the nucleus (Hoechst; blue), CD11b (red), and G6PD (green) was performed on the gonadal fat tissues
of db/
 and db/dbmice. Bars 100m (upper) and 50m (lower). (E to G) Relative levels of G6PDmRNA in human adipose tissues. (E) Correlation between
G6PD and several indices of obesity (BMI, waist circumference, visceral-fat area, and subcutaneous-fat area). (F) Correlation between G6PD and indices of
insulin resistance (IRI and HOMA-IR). (G) Correlation between G6PD and macrophage marker (CD68, MAC1, and MCP-1) genes.
Ham et al.
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phage G6PD would attenuate insulin sensitivity in adipocytes,
probably through secretion of proinflammatory cytokines.
Macrophage G6PD augments oxidative stress. It has been
well established that oxidative stress stimulates proinflammatory
signaling cascades (14, 25). Given that G6PD produces NADPH,
which plays a crucial role in the regulation of cellular redox, we
askedwhether the increase of proinflammatory gene expression in
macrophages mediated by G6PD is associated with oxidative
stress. To address this, we investigated the expression of ROS- and
RNS-producing genes and their products. As shown in Fig. 4A,
iNOS expression increased significantly in G6PD-overexpressing
macrophages. To determine the enzymatic activity of iNOS, the
level of nitrate, which is spontaneously generated from nitric ox-
ide (NO), was examined in conditioned media. In accordance
with the observed level of iNOS gene expression, the amount of
nitrate was higher in G6PD-overexpressing macrophages than in
control macrophages (Fig. 4B). Consistently, both basal and LPS-
induced levels of iNOSmRNAwere reduced in G6PD-suppressed
macrophages (see Fig. S4 in the supplemental material). More-
over, themRNA levels ofNOX2 components (p40phox, p47phox,
and p67phox) were also elevated by G6PD in macrophages (Fig.
4C). However, the mRNA levels of ROS-scavenging enzymes,
such as catalase and superoxide dismutase, were not altered by
G6PD (see Fig. S5 in the supplemental material). These results led
us to propose the idea that the G6PD-mediated increase in ROS-
and RNS-producing enzymes might confer cellular oxidative
stress in macrophages. To test this, cellular ROS levels were deter-
mined using a fluorescent dye. As shown in Fig. 4D, the basal level
of cellular ROS was increased by G6PD in primary macrophages.
In addition, stimulation with hydrogen peroxide further aug-
mented the level of cellular ROS inG6PD-overexpressing primary
macrophages. In contrast, suppression of G6PD expression by
siRNA reduced the level of cellular ROS in hydrogen peroxide-
treated RAW 264.7 macrophages (Fig. 4E). In these experiments,
hydrogen peroxide did not affect the viability of primary macro-
phages and RAW 264.7 macrophages (see Fig. S6 in the supple-
mental material). These results imply that augmentation of G6PD
would confer oxidative stress in macrophages.
In macrophages, ROS and RNS are important signaling mole-
cules that promote various signal transduction pathways linked to
proinflammatory responses (10, 11, 14, 26). To elucidate the po-
tential roles of ROS in G6PD-induced proinflammatory gene ex-
pression, macrophages were treated with the antioxidant NAC,
and the level of MCP-1, a representative proinflammatory gene,
was examined. As shown in Fig. 4F, NAC decreased the levels of
MCP-1mRNA in both control and G6PD-overexpressingmacro-
phages, implying that the increased oxidative stress mediated by
macrophage G6PD stimulates proinflammatory gene expression.
NADPHmediates the effects ofmacrophageG6PDonproin-
flammatory gene expression.NADPH participates in the regula-
tion of redox potential as one of the key redox pairs. To determine
whether the NADPH produced by G6PD is involved in oxidative
stress and proinflammatory responses in macrophages, macro-
phages were treated with NADPH. Treatment with NADPH in-
creased the level of intracellular NADPH inmacrophages (see Fig.
S7 in the supplemental material). Further, NADPH elevated cel-
lular ROS levels in macrophages (Fig. 5A) and modestly stimu-
lated the expression of proinflammatory genes and ROS/RNS-
producing genes (Fig. 5B). Therefore, these data indicate that the
effects of macrophage G6PD on oxidative stress and proinflam-
matory responses are mediated, at least in part, by increased cel-
lular NADPH.
p38 MAPK is activated by macrophage G6PD overexpres-
sion. It has been well established that oxidative stress in macro-
phages activatesMAPK signaling cascades, which play an essential
role in the regulation of gene expression (27). Although all 3
FIG 2 FFA and LPS stimulate G6PD expression in macrophages. (A and C) Induction of G6PD mRNA by treatment with FFA (palmitate) or LPS. RAW 264.7
macrophages were incubated with 100 M palmitate (A) or 100 ng/ml of LPS (C) for 24 h. IL-6, MCP-1, TNF-, and iNOS mRNAs were examined as positive
controls. The values are normalized to the levels of cyclophilin mRNA and are reported as the mean SD. *, P 0.05 versus vehicle; #, P 0.01 versus vehicle
(Student’s t test). (B) Level of G6PD protein upon treatment with FFA (palmitate). RAW 264.7 macrophages were treated with palmitate (100 M) for various
times. (D) Expression of G6PDprotein upon treatment with LPS. RAW264.7macrophages were incubatedwith 100 ng/ml of LPS for 24 h. CTL, negative control
for the LPS group. iNOS was used as a positive control for LPS treatment. (E) mRNA levels of NADPH-producing genes, such as G6PD, IDH1, andME1, upon
treatment with LPS. Cells were treated with 100 ng/ml of LPS for various times. The values are normalized to the levels of cyclophilin mRNA and are reported as
means SD. *, P 0.05 versus 0 h; #, P 0.01 versus 0 h (Student’s t test).
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MAPKs (ERK, p38 MAPK, and JNK) are activated by ROS, spe-
cific MAPKs appear to be activated, depending on the stimuli or
cell types (28–32). To understand the molecular mechanisms
underlying macrophage G6PD-mediated regulation of inflam-
matory gene expression, we investigated whether macrophage
G6PD affects MAPK activation. As shown in Fig. 6A, phos-
phorylation of p38 MAPK was evidently stimulated in G6PD-
overexpressing macrophages, while phosphorylation of ERK
and JNK was not altered. Furthermore, suppression of G6PD
with siG6PD or DHEA obviously attenuated the phosphoryla-
tion of p38 MAPK when the cells were challenged with LPS
(Fig. 6B and C). In addition, treatment with NADPH, an enzy-
matic product of G6PD, elevated the phosphorylation of p38
MAPK, and such increase was abolished by pretreatment with
NAC in macrophages (see Fig. S8 in the supplemental material). To
clarify the involvement of p38 MAPK in G6PD-induced proinflam-
matory gene expression, G6PD-overexpressing macrophages were
treated with a p38 MAPK inhibitor, SB 203580. The expression of
proinflammatory genes, such as the IL-6 and IL-1 genes, was signif-
icantly downregulated by SB 203580 (Fig. 6D), implying that p38
MAPKmediates the effects of G6PDon the expression of proinflam-
matory genes in macrophages.
Activation of NF-B contributes to the expression of proin-
flammatory genes in G6PD-overexpressing macrophages.
NF-B is a key transcription factor that is activated by oxidative
stress and governs the expression ofmost proinflammatory genes.
To examine the effect of G6PD on NF-B activation, we con-
ducted luciferase reporter assays using NF-B-responsive ele-
ments. As shown in Fig. 7A, G6PD overexpression in macro-
phages significantly stimulated the transcriptional activity of
NF-B. Furthermore, G6PD inhibitors, such as DHEA or 6-AN,
attenuated the transcriptional activity of NF-B. To verify the
involvement of NF-B in G6PD-induced proinflammatory gene
expression, the activity of NF-B was repressed with BAY 11-
7082, an inhibitor of IB phosphorylation. In macrophages, BAY
11-7082 reduced the levels of G6PD-induced IL-6 and MCP-1
mRNAs (Fig. 7B). Moreover, suppression of NF-B p50 with
siRNA greatly decreased the expression of proinflammatory genes
and ROS/RNS-producing genes, which were upregulated by
G6PD (Fig. 7C). Therefore, these data suggest that the increase
of G6PD in macrophages activates the transcriptional activity of
NF-B, which leads to elevation of proinflammatory and oxida-
tive-stress components in macrophages.
FIG 3 Macrophage G6PD modulates the expression of proinflammatory cytokines. (A) Levels of proinflammatory cytokine mRNAs in G6PD-overexpressing
macrophages. RAW 264.7 macrophages were transfected with EGFP or G6PD, and then total RNA was isolated to analyze the expression of G6PD, IL-6, IL-1,
MCP-1, andTNF-mRNAs by qRT-PCR. The values are normalized to the levels of cyclophilinmRNAand are reported asmeans SD. *,P 0.05 versus EGFP;
#, P 0.01 versus EGFP (Student’s t test). (B) Secretion of proinflammatory cytokines upon G6PD overexpression. Secreted IL-6 and MCP-1 cytokines were
measured in conditioned media from EGFP- or G6PD-overexpressing RAW 264.7 macrophages. The results are reported as means 
 SD. *, P  0.05 versus
EGFP; #, P 0.01 versus EGFP (Student’s t test). (C) Levels of IL-6 and MCP-1 mRNAs in G6PD-suppressed macrophages. After transfection with siGFP or
siG6PD, RAW264.7 cells were challengedwith LPS (100 ng/ml) for 3 h. The values are normalized to the levels of cyclophilinmRNAand are reported asmeans

SD. (D and E) Levels of IL-6 and MCP-1 mRNAs with or without G6PD inhibitors, such as DHEA (D) and 6-AN (E). Mouse peritoneal macrophages were
incubated with or without G6PD inhibitors (DHEA, 100 M; 6-AN, 100 M) and/or LPS (100 ng/ml). The values are normalized to the levels of cyclophilin
mRNA and are reported asmeans SD. *, P 0.05 versus DMSO-vehicle; #, P 0.01 versus DMSO-vehicle; &, P 0.05 versus DMSO-LPS ; §, P 0.01 versus
DMSO-LPS (Student’s t test). (F) Insulin sensitivity in adipocytes treated with conditioned media from G6PD-overexpressing macrophages. RAW 264.7
macrophages were transfected with EGFP or G6PD expression vector, and then conditioned media were harvested. Fully differentiated 3T3-L1 adipocytes were
treatedwith the conditionedmedia (24 h), followedby treatmentwith insulin (100nM) for 30min. Phosphorylation ofAKT (S473) andGSK3 (S9)was detected
using specific antibodies.
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DISCUSSION
In obese animals, adipose tissues exhibit chronic and low-grade
inflammation, which is a key contributor to various metabolic
disorders, such as insulin resistance, type 2 diabetes, cardiovascu-
lar disease, and atherosclerosis. Recent data have suggested that
dysregulation of several metabolites and their signaling pathways
is closely associatedwith inflammatory responses (3, 33).Here, we
show that macrophage G6PD, an enzyme that regulates glucose
flux, is elevated in the fat tissue of obese subjects and that macro-
phage G6PD promotes oxidative stress and proinflammatory re-
sponses, accompanied by p38 MAPK and NF-B activation.
It has been proposed that G6PD could act as an antioxidative
enzyme by producingNADPH, a key reducing cofactor for reduc-
tion of glutathione, which could alleviate oxidative stress (34–36).
For instance, G6PDdeficiency is a well-knownhuman enzymopa-
thy, which is characterized by hemolytic anemia due to increased
susceptibility to oxidative stress in red blood cells (37). However,
it is noteworthy that NADPH is also an essential cofactor for pro-
oxidative enzymes that generate ROS andRNS. For example, it has
been demonstrated that activation or overexpression of G6PD
increases NO production in RINm5F rat insulinoma cells and
bovine aortic endothelial cells (38, 39). Also, it has been reported
that inhibition of G6PD decreases ROS and RNS in various cell
types, includingmacrophages (40), granulocytes (20), and bovine
FIG 5 NADPH mediates the effect of G6PD on ROS production and proin-
flammatory gene expression. (A) ROS accumulation inNADPH-treated RAW
264.7 macrophages. RAW 264.7 macrophages were treated with NADPH (100
M) for 24 h. The results are reported as means  SD. *, P  0.05 versus
vehicle by Student’s t test. One representative histogram per group is shown.
(B) Levels of proinflammatory and ROS-producing genes in NADPH-treated
RAW264.7macrophages. The cells were treatedwithNADPH(100M) for 24
h. The values are normalized to the levels of cyclophilin mRNA and are re-
ported as means 
 SD. *, P  0.05 versus vehicle; #, P  0.01 versus vehicle
(Student’s t test).
FIG 4 Macrophage G6PD regulates the expression of ROS- and RNS-producing genes and their products. (A) mRNA levels of iNOS in G6PD-overexpressing
RAW 264.7 macrophages. The values are normalized to the levels of cyclophilin mRNA and are reported as means
 SD. *, P 0.05 versus EGFP by Student’s
t test. (B) Level of nitric oxide in G6PD-overexpressing macrophages. Conditioned media from EGFP- or G6PD-overexpressing macrophages were used to
measure nitrate concentrations. The results are reported as means
 SD. *, P 0.05 versus EGFP by Student’s t test. (C) mRNA levels of subunits of NADPH
oxidase (p40phox, p47phox, and p67phox) in G6PD-overexpressing RAW264.7macrophages. The values are normalized to the levels of cyclophilinmRNA and
are reported as means  SD. #, P  0.01 versus EGFP by Student’s t test. (D) Cellular ROS levels upon G6PD overexpression. After infection with Ad-mock
(Ad-M) or Ad-G6PD, peritonealmacrophages were treated with hydrogen peroxide (100M) for 20min. The cells were then incubated with the redox-sensitive
fluorescent dye chloromethyl-H2DCFDA for 10 min. The fluorescence intensity was measured using flow cytometry. The results are reported as means SD. *,
P  0.05 versus vehicle; #, P  0.01 versus vehicle (Student’s t test). One representative histogram per group is shown. (E) Cellular ROS levels in G6PD-
suppressed (siRNA)macrophages. After transfectionwith siGFPor siG6PD,RAW264.7macrophageswere treatedwith hydrogen peroxide (100M) for 20min.
The results are reported as means SD. *, P 0.05 versus vehicle; &, P 0.05 versus siGFP (Student’s t test). One representative histogram per group is shown.
(F) Level of MCP-1 mRNA after treatment with antioxidant. After transfection with EGFP or G6PD, cells were treated with NAC (20 mM) for 24 h. The results
are reported as means SD. #, P 0.01 versus EGFP; §, P 0.01 versus vehicle (Student’s t test).
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colonary arteries (41). Therefore, it is very likely that the physio-
logical roles of G6PD might be dependent on cell types that have
distinctmicroenvironments, with different levels of pro-oxidative
and antioxidative enzymes. In this study, we have demonstrated
that macrophage G6PD increases cellular oxidative stress by ele-
vation of ROS/RNS production, while knockdown or inhibition
of G6PD decreases cellular ROS.
It has been reported thatG6PD is involved in the inflammatory
responses of several immune cells. For example, macrophages de-
rived from G6PD-deficient mice exhibit more anti-inflammatory
potential than those from wild-type (WT) mice (42). Also,
mononuclear cells from G6PD-deficient patients secret fewer
proinflammatory cytokines than those from normal subjects
(43). Furthermore, severe G6PD deficiency resembles chronic
granulomatous disease in that granulocytes from G6PD-deficient
FIG 6 MAPK is involved in macrophage G6PD-induced inflammatory re-
sponses. (A) Phosphorylation of MAPKs, i.e., p38 MAPK (T180/Y182), ERK
(T202/Y204), and JNK (T183/Y185), after overexpression of G6PD. After in-
fection of peritoneal macrophages with adenovirus containing either Ad-
mock or Ad-G6PD, phosphorylated (p-) or basal MAPKs were detected in
total cell extracts. (B) Phosphorylation of MAPK after G6PD knockdown.
After transfection of macrophages with GFP or G6PD siRNA, the cells were
treated with LPS (L) (100 ng/ml) for 30 min and activation of MAPKs was
compared to control (C). (C) Phosphorylation of MAPK with the G6PD in-
hibitor DHEA. RAW 264.7 macrophages were pretreated with DMSO or
DHEA (100 M) for 24 h and then treated with LPS (100 ng/ml) for 30 min.
(D) Expression of proinflammatory genes in the presence or absence of p38
MAPK inhibitor (SB 203580). After transfection of RAW 264.7 macrophages
with EGFP orG6PD, the cells were treated with either vehicle or SB 203580 (10
M) for 24 h. The results are reported as means  SD. *, P  0.05 versus
EGFP-vehicle; #, P  0.01 versus EGFP-vehicle; &, P  0.05 versus G6PD-
vehicle; and §, P 0.01 versus G6PD-vehicle (Student’s t test).
FIG 7 Macrophage G6PD activates NF-B signaling. (A) Transcriptional ac-
tivity of NF-B with or without G6PD inhibitor treatment. An NF-B–lucif-
erase reporter was cotransfected into RAW 264.7 macrophages with EGFP or
G6PD. After transfection, the cells were treated with DMSO (DM), DHEA
(DH) (100M), or 6-AN (10M) for 24 h. The results are expressed in relative
luciferase units (luciferase activity/g protein) as means  SD. #, P  0.01
versus EGFP-DMSO; §, P  0.01 versus G6PD-DMSO (Student’s t test). (B)
Expression of IL-6 andMCP-1mRNAs after inhibition of NF-B. After trans-
fection of RAW264.7macrophages with EGFP or G6PD, the cells were treated
with BAY 11-7082 (5 M) for 24 h. The values are normalized to the levels of
cyclophilin and are reported as means
 SD. *, P 0.05 versus EGFP-vehicle;
†, P 0.11 versus G6PD-vehicle; ‡, P 0.05 versus G6PD-vehicle (Student’s
t test). (C) mRNA expression of several proinflammatory genes, NADPH-
producing genes, and ROS/RNS-producing genes in NF-B p50-suppressed
(siRNA) macrophages. siRNA (siNC or siNF-B p50) and expression vectors
(EGFPorG6PD)were cotransfected intoRAW264.7macrophages. The values
are normalized to the levels of cyclophilinmRNA and are reported asmeans
SD. *, P 0.05 versus siNC-EGFP; #, P 0.01 versus siNC-EGFP; &, P 0.05
versus siNFKB1-EGFP; and §, P  0.01 versus siNFKB1-EGFP (Student’s t
test).
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patients have a defect in the respiratory burst responsible for kill-
ing bacteria in granulocytes (44–46). In line with these findings, in
the present work, we report that increased G6PD expression in
macrophages promotes proinflammatory signaling cascades by
augmenting oxidative stress. Therefore, previous reports and our
current findings imply that macrophage G6PD would potentiate
proinflammatory responses.
Exposure to hydrogen peroxide or other stimuli that induce
cellular ROS leads to activation of MAPKs (29), while prevention
of ROS accumulation with antioxidants alleviates MAPK activa-
tion (47, 48), implying that MAPKs are key players in the propa-
gation of oxidative stresses as a target of ROS. Although themech-
anisms by which exogenously or endogenously produced ROS
activates MAPKs are not yet thoroughly understood, several
mechanisms have been proposed. In macrophages, we observed
that G6PD selectively activated p38 MAPK, with slight activation
of JNK or ERK. Interestingly, activation of p38 MAPK challenged
with LPS was remarkably attenuated by suppression of G6PD via
siRNA or DHEA. Furthermore, inhibition of p38 MAPK with SB
203580 repressed basal and G6PD-induced proinflammatory
gene expression inmacrophages. These results clearly suggest that
activation of p38MAPKplays a crucial role inmacrophageG6PD-
induced proinflammatory responses under pathophysiological
stimuli.
In addition, we discovered that macrophage G6PD activated
NF-B, which was assessed by its transcriptional activity and tar-
get gene expression. NF-B is a well-known master regulator of
inflammatory responses (49). Previously, it has been reported that
ROS promotes the transcriptional activity of NF-B through sev-
eral mechanisms, such as phosphorylation of RelA (12, 50) and
activation of IB kinase (IKK) (51). Although we observed that
inhibition of NF-B greatly suppressed G6PD-induced proin-
flammatory responses, we could not exclude the possibility that
other transcription factors also contribute to G6PD-induced pro-
inflammatory responses in macrophages. For instance, several
transcription factors, such as Sp1, AP-1, p53, and HIF-1, have
been reported to be redox-responsive transcription factors that
appear to be differentially activated by oxidative stresses to exert
proinflammatory responses (52, 53).
Various cellular signaling pathways influence each other
through biochemical and physiological cross talk. For example,
the p38 MAPK pathway plays a role in NF-B activation (54–57).
In this study, we revealed that macrophage G6PD activated p38
MAPK and NF-B, while suppression or inhibition of macro-
phage G6PD reduced both of them. In addition, we observed that
inhibition of p38 MAPK attenuated the transcriptional activity of
NF-B induced by macrophage G6PD (see Fig. S9 in the supple-
mental material). Taken together, these data suggest that G6PD-
induced expression of proinflammatory cytokines might be me-
diated, at least in part, by p38 MAPK-dependent activation of
NF-B. Nevertheless, it is still plausible that macrophage G6PD-
mediated activation of p38 MAPK and NF-B constitutes a posi-
tive-feedback loop that amplifies proinflammatory responses.
Inflammatory diseases, including atherosclerosis (58), nonal-
coholic steatohepatitis (59), and heart failure (60), deteriorate via
vicious cycles between oxidative stress and inflammation. Simi-
larly, it appears that a vicious cycle may play a role in the progres-
sion of dysregulated fat tissue in obese subjects, which commonly
exhibits chronic and low-grade inflammation due to the accumu-
lation of ATMs. Our data suggest thatmacrophageG6PD supplies
NADPH to stimulate pro-oxidative enzymes, such as iNOS and
NADPH oxidase, leading to increased cellular RNS and ROS.
Then, ROS andRNS induce the expression ofNF-B-target genes,
including ROS/RNS-producing enzymes and proinflammatory
genes, which attenuate insulin signaling in adipocytes. Accord-
ingly, we observed that knockdown of G6PD or treatment with
G6PD inhibitors decreased cellular ROS and the expression of
ROS/RNS-producing enzymes in macrophages. Therefore, it is
reasonable to speculate that augmentation of macrophage G6PD
might contribute to chronic and low-grade inflammatory signal-
ing by accelerating a vicious cycle as follows: ROS/RNS¡p38
MAPK¡NF-B¡ROS/RNS-producing enzymes.
In the present study, we elucidated the pathophysiological
roles of macrophage G6PD in obesity. Among the various envi-
ronmental factors, FFAs and LPS promote G6PD expression in
macrophages. Subsequent elevation of macrophage G6PD in-
creases oxidative stress and activates p38 MAPK and NF-B,
which eventually stimulate proinflammatory genes and ROS/
RNS-signaling cascades. Therefore, it appears that identifying the
regulatory tools formacrophageG6PD could provide a promising
treatment for inflammation- and/or oxidative-stress-linked met-
abolic diseases, such as obesity and type 2 diabetes.
ACKNOWLEDGMENTS
We thank Y. J. Koh and G. Y. Koh for their technical assistance with
whole-mount immunohistochemistry.
This work was supported by grants from the Korea Science and Engi-
neering Foundation funded by the South Korean government (Ministry
of Education, Science, and Technology) (20120006079, 2012-0001241,
and R31-10032). M.H., H.J., and G.C. were supported by BK21 Research
Fellowships from the Ministry of Education and Human Resources De-
velopment.
We declare that we have no conflict of interest.
REFERENCES
1. Kahn SE, Hull RL, Utzschneider KM. 2006. Mechanisms linking obesity
to insulin resistance and type 2 diabetes. Nature 444:840–846.
2. Lumeng CN, Saltiel AR. 2011. Inflammatory links between obesity and
metabolic disease. J. Clin. Invest. 121:2111–2117.
3. Shoelson SE, Lee J, Goldfine AB. 2006. Inflammation and insulin resis-
tance. J. Clin. Invest. 116:1793–1801.
4. Hotamisligil GS, Shargill NS, Spiegelman BM. 1993. Adipose expression
of tumor necrosis factor-alpha: direct role in obesity-linked insulin resis-
tance. Science 259:87–91.
5. Ito A, Suganami T, Yamauchi A, Degawa-Yamauchi M, Tanaka M,
Kouyama R, Kobayashi Y, Nitta N, Yasuda K, Hirata Y, Kuziel WA,
Takeya M, Kanegasaki S, Kamei Y, Ogawa Y. 2008. Role of CC chemo-
kine receptor 2 in bone marrow cells in the recruitment of macrophages
into obese adipose tissue. J. Biol. Chem. 283:35715–35723.
6. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa
S, Miyachi H, Maeda S, Egashira K, Kasuga M. 2006. MCP-1 contributes
to macrophage infiltration into adipose tissue, insulin resistance, and he-
patic steatosis in obesity. J. Clin. Invest. 116:1494–1505.
7. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K,
Charo I, Leibel RL, Ferrante AW, Jr. 2006. CCR2 modulates inflamma-
tory andmetabolic effects of high-fat feeding. J. Clin. Invest. 116:115–124.
8. Olefsky JM, Glass CK. 2010. Macrophages, inflammation, and insulin
resistance. Annu. Rev. Physiol. 72:219–246.
9. Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E,
Ostroff GR, Czech MP. 2009. Orally delivered siRNA targeting macro-
phage Map4k4 suppresses systemic inflammation. Nature 458:1180–
1184.
10. Gwinn MR, Vallyathan V. 2006. Respiratory burst: role in signal trans-
duction in alveolar macrophages. J. Toxicol. Environ. Health B Crit. Rev.
9:27–39.
11. Fialkow L, Wang Y, Downey GP. 2007. Reactive oxygen and nitrogen
Role of Macrophage G6PD in Proinﬂammatory Cascade
June 2013 Volume 33 Number 12 mcb.asm.org 2433
 o
n
 O
ctober 12, 2014 by ULSAN NATIO
NAL INS O
F SCIENCE & TECHNO
LO
G
Y(UNIST)
http://m
cb.asm
.org/
D
ow
nloaded from
 
species as signaling molecules regulating neutrophil function. Free Radic.
Biol. Med. 42:153–164.
12. Schreck R, Rieber P, Baeuerle PA. 1991. Reactive oxygen intermediates as
apparently widely used messengers in the activation of the NF-kappa B
transcription factor and HIV-1. EMBO J. 10:2247–2258.
13. Lo YY, Cruz TF. 1995. Involvement of reactive oxygen species in cytokine
and growth factor induction of c-fos expression in chondrocytes. J. Biol.
Chem. 270:11727–11730.
14. Forman HJ, Torres M. 2001. Redox signaling in macrophages. Mol.
Aspects Med. 22:189–216.
15. Emre Y, Nubel T. 2010. Uncoupling protein UCP2: when mitochondrial
activity meets immunity. FEBS Lett. 584:1437–1442.
16. Lambeth JD. 2004. NOX enzymes and the biology of reactive oxygen. Nat.
Rev. Immunol. 4:181–189.
17. Park J, Rho HK, Kim KH, Choe SS, Lee YS, Kim JB. 2005. Overexpres-
sion of glucose-6-phosphate dehydrogenase is associated with lipid dys-
regulation and insulin resistance in obesity.Mol. Cell. Biol. 25:5146–5157.
18. Lee JW, Choi AH, HamM, Kim JW, Choe SS, Park J, Lee GY, Yoon KH,
Kim JB. 2011. G6PD up-regulation promotes pancreatic beta-cell dys-
function. Endocrinology 152:793–803.
19. Park J, Choe SS, Choi AH, Kim KH, Yoon MJ, Suganami T, Ogawa Y,
Kim JB. 2006. Increase in glucose-6-phosphate dehydrogenase in adi-
pocytes stimulates oxidative stress and inflammatory signals. Diabetes 55:
2939–2949.
20. Tsai KJ, Hung IJ, Chow CK, Stern A, Chao SS, Chiu DT. 1998. Impaired
production of nitric oxide, superoxide, and hydrogen peroxide in glucose
6-phosphate-dehydrogenase-deficient granulocytes. FEBS Lett. 436:411–
414.
21. Kim KH, Yoon JM, Choi AH, Kim WS, Lee GY, Kim JB. 2009. Liver X
receptor ligands suppress ubiquitination and degradation of LXRalpha by
displacing BARD1/BRCA1. Mol. Endocrinol. 23:466–474.
22. Salati LM, Amir-Ahmady B. 2001. Dietary regulation of expression of
glucose-6-phosphate dehydrogenase. Annu. Rev. Nutr. 21:121–140.
23. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. 1995.
Increased adipose tissue expression of tumor necrosis factor-alpha in hu-
man obesity and insulin resistance. J. Clin. Invest. 95:2409–2415.
24. Suganami T, Nishida J, Ogawa Y. 2005. A paracrine loop between adi-
pocytes and macrophages aggravates inflammatory changes: role of free
fatty acids and tumor necrosis factor alpha. Arterioscler. Thromb. Vasc.
Biol. 25:2062–2068.
25. Han CY, Umemoto T, Omer M, Den Hartigh LJ, Chiba T, LeBoeuf R,
Buller CL, Sweet IR, Pennathur S, Abel ED, Chait A. 2012. NADPH
oxidase-derived reactive oxygen species increases expression of monocyte
chemotactic factor genes in cultured adipocytes. J. Biol. Chem. 287:
10379–10393.
26. Kamata H, Hirata H. 1999. Redox regulation of cellular signalling. Cell
Signal. 11:1–14.
27. Torres M, Forman HJ. 2003. Redox signaling and the MAP kinase path-
ways. Biofactors 17:287–296.
28. Gao D, Nong S, Huang X, Lu Y, Zhao H, Lin Y, Man Y, Wang S, Yang
J, Li J. 2010. The effects of palmitate on hepatic insulin resistance are
mediated by NADPH oxidase 3-derived reactive oxygen species through
JNK and p38MAPK pathways. J. Biol. Chem. 285:29965–29973.
29. Guyton KZ, Liu Y, Gorospe M, Xu Q, Holbrook NJ. 1996. Activation of
mitogen-activated protein kinase by H2O2. Role in cell survival following
oxidant injury. J. Biol. Chem. 271:4138–4142.
30. Ishiyama J, Taguchi R, Yamamoto A, Murakami K. 2010. Palmitic acid
enhances lectin-like oxidized LDL receptor (LOX-1) expression and pro-
motes uptake of oxidized LDL in macrophage cells. Atherosclerosis 209:
118–124.
31. Wang X, Martindale JL, Liu Y, Holbrook NJ. 1998. The cellular response
to oxidative stress: influences of mitogen-activated protein kinase signal-
ling pathways on cell survival. Biochem. J. 333:291–300.
32. Yuan H, Zhang X, Huang X, Lu Y, Tang W, Man Y, Wang S, Xi J., Li
J. 2010. NADPH oxidase 2-derived reactive oxygen species mediate FFAs-
induced dysfunction and apoptosis of beta-cells via JNK, p38 MAPK and
p53 pathways. PLoS One 5:e15726. doi:10.1371/journal.pone.0015726.
33. Haschemi A, Kosma P, Gille L, Evans CR, Burant CF, Starkl P, Knapp
B, Haas R, Schmid JA, Jandl C, Amir S, Lubec G, Park J, Esterbauer H,
Bilban M, Brizuela L, Pospisilik JA, Otterbein LE, Wagner O. 2012. The
sedoheptulose kinase CARKL directs macrophage polarization through
control of glucose metabolism. Cell Metab. 15:813–826.
34. Cosentino C, Grieco D, Costanzo V. 2011. ATM activates the pentose
phosphate pathway promoting anti-oxidant defence and DNA repair.
EMBO J. 30:546–555.
35. Leopold JA, Zhang YY, Scribner AW, Stanton RC, Loscalzo J. 2003.
Glucose-6-phosphate dehydrogenase overexpression decreases endothe-
lial cell oxidant stress and increases bioavailable nitric oxide. Arterioscler.
Thromb. Vasc. Biol. 23:411–417.
36. Gaetani GD, Parker JC, Kirkman HN. 1974. Intracellular restraint: a new
basis for the limitation in response to oxidative stress in human erythro-
cytes containing low-activity variants of glucose-6-phosphate dehydroge-
nase. Proc. Natl. Acad. Sci. U. S. A. 71:3584–3587.
37. Frank JE. 2005. Diagnosis andmanagement of G6PDdeficiency. Am. Fam
Physician 72:1277–1282.
38. Guo L, Zhang Z, Green K, Stanton RC. 2002. Suppression of interleu-
kin-1 beta-induced nitric oxide production in RINm5F cells by inhibition
of glucose-6-phosphate dehydrogenase. Biochemistry 41:14726–14733.
39. Leopold JA, Walker J, Scribner AW, Voetsch B, Zhang YY, Loscalzo AJ,
Stanton RC, Loscalzo J. 2003. Glucose-6-phosphate dehydrogenase
modulates vascular endothelial growth factor-mediated angiogenesis. J.
Biol. Chem. 278:32100–32106.
40. Hothersall JS, Gordge M, Noronha-Dutra AA. 1998. Inhibition of
NADPH supply by 6-aminonicotinamide: effect on glutathione, nitric
oxide and superoxide in J774 cells. FEBS Lett. 434:97–100.
41. Gupte SA, Arshad M, Viola S, Kaminski PM, Ungvari Z, Rabbani G,
Koller A, Wolin MS. 2003. Pentose phosphate pathway coordinates mul-
tiple redox-controlled relaxing mechanisms in bovine coronary arteries.
Am. J. Physiol. Heart Circ. Physiol. 285:H2316–H2326.
42. Wilmanski J, Siddiqi M, Deitch EA, Spolarics Z. 2005. Augmented IL-10
production and redox-dependent signaling pathways in glucose-6-
phosphate dehydrogenase-deficient mouse peritoneal macrophages. J.
Leukoc. Biol. 78:85–94.
43. Sanna F, Bonatesta RR, Frongia B, Uda S, Banni S, Melis MP, Collu M,
Madeddu C, Serpe R, Puddu S, Porcu G, Dessi S, Batetta B. 2007.
Production of inflammatory molecules in peripheral blood mononuclear
cells from severely glucose-6-phosphate dehydrogenase-deficient sub-
jects. J. Vasc. Res. 44:253–263.
44. Roos D, van Zwieten R, Wijnen JT, Gomez-Gallego F, de Boer M,
Stevens D, Pronk-Admiraal CJ, de Rijk T, van Noorden CJ, Weening
RS, Vulliamy TJ, Ploem JE, Mason PJ, Bautista JM, Khan PM, Beutler
E. 1999.Molecular basis and enzymatic properties of glucose 6-phosphate
dehydrogenase volendam, leading to chronic nonspherocytic anemia,
granulocyte dysfunction, and increased susceptibility to infections. Blood
94:2955–2962.
45. van Bruggen R, Bautista JM, Petropoulou T, de Boer M, van Zwieten R,
Gomez-Gallego F, Belohradsky BH, Hartwig NG, Stevens D, Mason PJ,
Roos D. 2002. Deletion of leucine 61 in glucose-6-phosphate dehydroge-
nase leads to chronic nonspherocytic anemia, granulocyte dysfunction,
and increased susceptibility to infections. Blood 100:1026–1030.
46. Cooper MR, DeChatelet LR, McCall CE, LaVia MF, Spurr CL,
Baehner RL. 1972. Complete deficiency of leukocyte glucose-6-
phosphate dehydrogenase with defective bactericidal activity. J. Clin.
Invest. 51:769–778.
47. Kyaw M, Yoshizumi M, Tsuchiya K, Kirima K, Tamaki T. 2001. Anti-
oxidants inhibit JNKandp38MAPKactivation but not ERK1/2 activation
by angiotensin II in rat aortic smooth muscle cells. Hypertens. Res. 24:
251–261.
48. Sekharam M, Cunnick JM, Wu J. 2000. Involvement of lipoxygenase in
lysophosphatidic acid-stimulated hydrogen peroxide release in human
HaCaT keratinocytes. Biochem. J. 346:751–758.
49. Baker RG, Hayden MS, Ghosh S. 2011. NF-kappaB, inflammation, and
metabolic disease. Cell Metab. 13:11–22.
50. Nowak DE, Tian B, Jamaluddin M, Boldogh I, Vergara LA, Choud-
hary S, Brasier AR. 2008. RelA Ser276 phosphorylation is required for
activation of a subset of NF-kappaB-dependent genes by recruiting
cyclin-dependent kinase 9/cyclin T1 complexes. Mol. Cell. Biol. 28:
3623–3638.
51. Kamata H, Manabe T, Oka S, Kamata K, Hirata H. 2002. Hydrogen
peroxide activates IkappaB kinases through phosphorylation of serine res-
idues in the activation loops. FEBS Lett. 519:231–237.
52. Hui X, Li H, Zhou Z, Lam KS, Xiao Y, Wu D, Ding K, Wang Y,
Vanhoutte PM, Xu A. 2010. Adipocyte fatty acid-binding protein mod-
ulates inflammatory responses in macrophages through a positive feed-
back loop involving c-Jun NH2-terminal kinases and activator protein-1.
J. Biol. Chem. 285:10273–10280.
Ham et al.
2434 mcb.asm.org Molecular and Cellular Biology
 o
n
 O
ctober 12, 2014 by ULSAN NATIO
NAL INS O
F SCIENCE & TECHNO
LO
G
Y(UNIST)
http://m
cb.asm
.org/
D
ow
nloaded from
 
53. Nishi K, Oda T, Takabuchi S, Oda S, Fukuda K, Adachi T, Semenza GL,
Shingu K, Hirota K. 2008. LPS induces hypoxia-inducible factor 1 acti-
vation in macrophage-differentiated cells in a reactive oxygen species-
dependent manner. Antioxid. Redox Signal. 10:983–995.
54. Beyaert R, Cuenda A, Vanden Berghe W, Plaisance S, Lee JC, Haege-
man G, Cohen P, Fiers W. 1996. The p38/RK mitogen-activated protein
kinase pathway regulates interleukin-6 synthesis response to tumor necro-
sis factor. EMBO J. 15:1914–1923.
55. Craig R, Larkin A, Mingo AM, Thuerauf DJ, Andrews C, McDonough
PM, Glembotski CC. 2000. p38 MAPK and NF-kappa B collaborate to
induce interleukin-6 gene expression and release. Evidence for a cytopro-
tective autocrine signaling pathway in a cardiac myocyte model system. J.
Biol. Chem. 275:23814–23824.
56. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J., Chen ZJ. 2001.
TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412:
346–351.
57. Zechner D, Craig R, Hanford DS, McDonough PM, Sabbadini RA,
Glembotski CC. 1998. MKK6 activates myocardial cell NF-kappaB and
inhibits apoptosis in a p38 mitogen-activated protein kinase-dependent
manner. J. Biol. Chem. 273:8232–8239.
58. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. 2003.
Role of oxidative stress in atherosclerosis. Am. J. Cardiol. 91:7A–11A.
59. Begriche K, Igoudjil A, Pessayre D, Fromenty B. 2006. Mitochondrial
dysfunction in NASH: causes, consequences and possible means to pre-
vent it. Mitochondrion 6:1–28.
60. Khaper N, Bryan S, Dhingra S, Singal R, Bajaj A, Pathak CM, Singal PK.
2010. Targeting the vicious inflammation-oxidative stress cycle for the
management of heart failure. Antioxid. Redox Signal. 13:1033–1049.
Role of Macrophage G6PD in Proinﬂammatory Cascade
June 2013 Volume 33 Number 12 mcb.asm.org 2435
 o
n
 O
ctober 12, 2014 by ULSAN NATIO
NAL INS O
F SCIENCE & TECHNO
LO
G
Y(UNIST)
http://m
cb.asm
.org/
D
ow
nloaded from
 
